S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)

OmniAb Stock Price, News & Analysis (NASDAQ:OABI)

$4.79
+0.08 (+1.70%)
(As of 02:42 PM ET)
Compare
Today's Range
$4.58
$4.80
50-Day Range
$4.23
$5.31
52-Week Range
$3.06
$5.97
Volume
414,302 shs
Average Volume
568,114 shs
Market Capitalization
$556.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75

OmniAb MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
107.9% Upside
$9.75 Price Target
Short Interest
Healthy
4.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of OmniAb in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$405,650 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

259th out of 948 stocks

Commercial Physical Research Industry

4th out of 11 stocks


OABI stock logo

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

OABI Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Matthew Foehr Bought 4.1% More Shares In OmniAb
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
OmniAb Appoints Steve Love to its Board of Directors
OmniAb: Hold For Growth
OABIW OmniAb, Inc. WT EXP 110127
OmniAb President Acquires 2.0% More Stock
Truist Financial Remains a Buy on OmniAb (OABI)
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$13.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+107.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-22,330,000.00
Pretax Margin
-53.64%

Debt

Sales & Book Value

Annual Sales
$59.08 million
Book Value
$2.96 per share

Miscellaneous

Free Float
108,101,000
Market Cap
$547.49 million
Optionable
Not Optionable
Beta
-0.40
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Matthew W. Foehr (Age 50)
    President, CEO & Director
    Comp: $967.72k
  • Mr. Kurt A. Gustafson (Age 55)
    Executive VP of Finance & CFO
    Comp: $558.48k
  • Mr. Charles S. Berkman J.D. (Age 54)
    Chief Legal Officer & Secretary
    Comp: $734.33k
  • Ms. Cia McCaffrey
    Vice President of People & Talent
  • Dr. Bill Harriman Ph.D.
    Senior Vice President of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Senior Vice President of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Senior Vice President of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 65)
    Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Senior Vice President of Corporate Controller














OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price target for 2024?

8 equities research analysts have issued 1-year price objectives for OmniAb's stock. Their OABI share price targets range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 107.9% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2023?

OmniAb's stock was trading at $3.60 on January 1st, 2023. Since then, OABI shares have increased by 30.3% and is now trading at $4.69.
View the best growth stocks for 2023 here
.

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our OABI earnings forecast
.

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02. The firm had revenue of $5.48 million for the quarter, compared to analysts' expectations of $11.37 million. OmniAb had a negative trailing twelve-month return on equity of 8.88% and a negative net margin of 45.99%.

Who are OmniAb's major shareholders?

OmniAb's stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (2.75%), William Blair Investment Management LLC (2.46%), Rubric Capital Management LP (2.45%), Rubric Capital Management LP (2.45%), Rice Hall James & Associates LLC (2.39%) and Private Management Group Inc. (2.30%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -